From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from a recent survey of a critical mass of diagnostic labs in the U.S, with analysis from Kalorama’s leading diagnostic analyst, Shara Rosen.
Far more than any other market research report, this report provides the most current and accurate picture of what is truly going on in molecular diagnostics in the United States.
Analyzed by the best-selling author of The Worldwide Market for In Vitro Diagnostics, now in its sixth edition, this new report includes surveys of molecular diagnostics focusing on these tests:
- Chlamydia and Gonorrhea
- HBV Viral Load
- HCV Viral Load, HCV Genotyping
- HIV Viral Load, HIV Genotyping
- HPV, HPV Genotyping
- Hospital Acquired Infections – MRSA, VRE
- Coagulation Factors – Factor II, Factor V Leiden
- Herpes Simplex Virus (HSV)
- Oncology Tests – BCR/ABL, Bladder Cancer, Her2Neu, MTHFR
- Transplant Medicine – HLA Typing
- Hereditary Disorders – Cystic Fibrosis (CF), Fragile X
- Respiratory Infections – Influenza A/B, Group A Strep, MTB (Tuberculosis), Bordetella pertussis, Adenovirus, Respiratory Virus
- Communicable Diseases – CMV (Cytomegalovirus), EBV (Epstein-Barr Virus), Group B Strep, Enterovirus
What Labs Do Now, What They are Planning in the Future
There has been much analysis in recent years about the inroads that DNA testing has made. This unique resource offers a way to measure that progress, and test assumptions aobut the evolution of DNA testing, critical information to adjust business stratetgies. This report looks at the following topics:
- What type of reagents are labs using (Commercial, ASR, Homebrew)
- Where tests are performed (Central/Core Testing Lab, Chemistry Lab, Cytology Lab, Genetics Lab, Hematology Lab, Microbiology Lab, Molecular Lab, Pathology Lab, Serology/Immunology Lab, Virology Lab)
- What Vendors are Labs Using
- What are there Purchasing Plans
- What Tests Do They Want in the Future
- Do They Outsource and at what Rate?
- Do They plan Vendor Changes?
A Representative Sample of the US Hospital Lab Industry
Emmes Group reached an extensive sample group – interviewing 14% of US hospital labs, 14% of public labs and 8% of US reference lab, where Emmes respondent numbers are compared to the Americian Hospital Directory. Such an undertaking would cost an individual company tens of thousands of dollars. This information is available to purchasers of this report at a fraction of the cost.